Briacell Therapeutics
BCTX
18 hedge funds and large institutions have $12.3M invested in Briacell Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
2,659% more call options, than puts
Call options by funds: $3.2M | Put options by funds: $116K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.84% more ownership
Funds ownership: 16.33% → 17.17% (+0.84%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
14% less capital invested
Capital invested by funds: $14.3M → $12.3M (-$1.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$1.87M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$299K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$77.9K |
| 4 |
N
Natixis
Paris,
France
|
+$70.3K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$66.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$546K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$464K |
| 3 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$295K |
| 4 |
VF
Virtu Financial
New York
|
-$158K |
| 5 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$101K |
BCTX Hedge Fund Activity: Q4 2022 in Review
18 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q4 2022, worth a combined $12.3M — down 14% from $14.3M a quarter earlier.
Fund positioning in BCTX was balanced in Q4 2022: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Lynwood Capital Management, adding an estimated $1.87M. The largest seller was Jane Street, exiting entirely with an estimated $546K sold.
- 18 institutional investors held Briacell Therapeutics (BCTX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $12.3M of Briacell Therapeutics stock for Q4 2022, down 14% quarter-over-quarter.
- 5 funds opened new Briacell Therapeutics positions in Q4 2022 and 5 closed out, a net change of 0 holders.
- The largest Briacell Therapeutics buyer in Q4 2022 was Lynwood Capital Management, an estimated $1.87M added.
- The largest Briacell Therapeutics seller in Q4 2022 was Jane Street, an estimated $546K sold.
Based on aggregated 13F filings for Q4 2022.